Inici › Càncer d'endometri › Florida › Miami
Assaigs clínics de Càncer d'endometri a Miami, FL
16 estudis de Càncer d'endometri busquen participants en centres de Miami i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
ReclutantFase 2
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutantFase 1/2
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
ReclutantEstudi observacional
- Genoma Research, Inc., Miami
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance
ReclutantFase 2
- University of Miami, Miami
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
ReclutantFase 2
- University of Miami School of Medicine, Miami
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
ReclutantFase 1
- Sylvester Comprehensive Cancer Center, Miami
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
ReclutantFase 1
- University of Miami, Miami
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
ReclutantFase 3
- Research Site, Miami
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
ReclutantEstudi observacional
- Miami Cancer Institute Baptist Health South Florida, Miami
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
ReclutantFase 1
- University of Miami, Miami
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
ReclutantFase 3
- Research Site, Miami
- Research Site, Miami
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
ReclutantFase 3
- Miami Cancer Institute, Miami
Fasting InTervention for Endometrial Cancer
Reclutant
- University of Miami, Miami
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ReclutantFase 1/2
- Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Miami Cancer Institute, Miami
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Miami
Assaigs de Càncer d'endometri en altres ciutats
- Houston, TX68 estudis
- New York City, NY52 estudis
- Boston, MA50 estudis
- Arlington, VA39 estudis
- Nashville, TN38 estudis
- Los Angeles, CA34 estudis
- St. Louis, MO29 estudis
- Philadelphia, PA28 estudis
- San Antonio, TX27 estudis
- Queens, NY25 estudis
- Columbus, OH25 estudis
- Chicago, IL25 estudis
Altres estudis a Miami
- Càncer de mama42 estudis
- Càncer (tots els tipus)36 estudis
- Càncer de pulmó de cèl·lules no petites31 estudis
- Càncer de pròstata27 estudis
- Obesitat27 estudis
- Leucèmia mieloide aguda24 estudis
- Càncer metastàtic24 estudis
- Càncer d'ovari23 estudis
- Sobrepès23 estudis
- Mieloma múltiple21 estudis
- Colitis ulcerosa21 estudis
- Malaltia d'Alzheimer20 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.